Ischaemic heart disease is a leading cause of death worldwide. Injury to the heart is
followed by loss of the damaged cardiomyocytes, which are replaced with fibrotic scar …

A large number of clinical trials have shown stem cell therapy to be a promising therapeutic
approach for the treatment of cardiovascular diseases. Since the first transplantation into …

1.1. Methodology and Evidence Review The recommendations listed in this document are,
whenever possible, evidence based. The current document constitutes a full revision and …

Current therapies for heart failure after myocardial infarction are limited and non-curative.
Although regenerative approaches are receiving significant attention, clinical efforts that …

Context Mesenchymal stem cells (MSCs) are under evaluation as a therapy for ischemic
cardiomyopathy (ICM). Both autologous and allogeneic MSC therapies are possible; …

Summary Background Cardiosphere-derived cells (CDCs) reduce scarring after myocardial
infarction, increase viable myocardium, and boost cardiac function in preclinical models. We …

Heart failure (HF) affects 60 million people worldwide and has developed into a global
public health problem surpassing cancer and urgently needs to be solved. According to the …

Mesenchymal stem cells (MSCs) are broadly distributed cells that retain postnatal capacity
for self-renewal and multilineage differentiation. MSCs evade immune detection, secrete an …

Rationale: Cardiac remodeling and subsequent heart failure remain critical issues after
myocardial infarction despite improved treatment and reperfusion strategies. Recently …

Importance Stem cell therapy is a promising treatment strategy for patients with heart failure,
which accounts for more than 10% of deaths in the United States annually. Despite more …